MAPT and Alzheimer disease: New NIA-AA recommendations for defining “MCI due to AD – high likelihood”27, which require positive pathological (molecular imaging or spinal fluid tests of beta-amyloid and tau) and/or neuronal loss (structural MR imaging) biomarkers in addition to clinical criteria, were, in part, based on MCI data from ADNI.